All In Biotech

Drug Trial Radar · NCT04806464

Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer

A Dose Ascending, Open Phase I Clinical Study to Evaluate the Safety, Tolerability , Pharmacokinetics Characteristics and Preliminary Effectiveness of VG161 in Subjects with Advanced Primary Liver Cancer

Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

44

Planned (sponsor's estimate)

Start

Mar 16, 2021

Primary completion

Mar 21, 2022

Study completion Dec 31, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This phase I study will be conducted in HSV-seropositive subjects with advanced primary liver cancer that are refractory to conventional therapies. This is an open label study and it's divided into two parts. Part 1: This part is ascending dose design to determine the safety and tolerability of VG161 and find recommended dose of VG161. Part 2: This part is extended dose design to determine the effectiveness of VG161.

Conditions

  • Primary Liver Cancer

Interventions

  • Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))Drug

    Intratumoral injection only. The dosing date can be the Day 1 only or Days 1 through 5.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part1: MTD/Recommended doseTime frame: 7 month
  2. Part1: Occurence of DLTTime frame: 1month
  3. Part1: Numbers of DLTTime frame: 1 month
  4. Part1: Occurence of AE and SAE(NCI CTCAE 5.0)Time frame: 7 months
  5. Part1: Frequency of AE and SAE(NCI CTCAE 5.0)Time frame: 7 months
  6. Part2:ORRTime frame: 7 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.